Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 34

Cited In for PubMed (Select 16863503)

1.

RNA interference targeting enhancer of polycomb1 exerts anti-tumor effects in lung cancer.

Che C, Zhang L, Huo J, Zhang Y.

Int J Clin Exp Pathol. 2015 Jan 1;8(1):361-7. eCollection 2015.

2.

Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer.

Fujita Y, Yagishita S, Takeshita F, Yamamoto Y, Kuwano K, Ochiya T.

Oncotarget. 2015 Feb 20;6(5):3335-45.

3.

A novel platform to enable inhaled naked RNAi medicine for lung cancer.

Fujita Y, Takeshita F, Mizutani T, Ohgi T, Kuwano K, Ochiya T.

Sci Rep. 2013 Nov 25;3:3325. doi: 10.1038/srep03325.

4.

Allele dependent silencing of collagen type I using small interfering RNAs targeting 3'UTR Indels - a novel therapeutic approach in osteogenesis imperfecta.

Lindahl K, Kindmark A, Laxman N, Åström E, Rubin CJ, Ljunggren Ö.

Int J Med Sci. 2013 Aug 13;10(10):1333-43. doi: 10.7150/ijms.5774. eCollection 2013.

5.

Local applications of myostatin-siRNA with atelocollagen increase skeletal muscle mass and recovery of muscle function.

Kawakami E, Kawai N, Kinouchi N, Mori H, Ohsawa Y, Ishimaru N, Sunada Y, Noji S, Tanaka E.

PLoS One. 2013 May 22;8(5):e64719. doi: 10.1371/journal.pone.0064719. Print 2013.

6.

Gene therapy for cardiovascular disease mediated by ultrasound and microbubbles.

Chen ZY, Lin Y, Yang F, Jiang L, Ge Sp.

Cardiovasc Ultrasound. 2013 Apr 17;11:11. doi: 10.1186/1476-7120-11-11. Review.

7.

Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma.

Fujiwara-Okada Y, Matsumoto Y, Fukushi J, Setsu N, Matsuura S, Kamura S, Fujiwara T, Iida K, Hatano M, Nabeshima A, Yamada H, Ono M, Oda Y, Iwamoto Y.

Br J Cancer. 2013 Mar 5;108(4):836-47. doi: 10.1038/bjc.2012.579.

8.

Therapeutic effects of microRNA-582-5p and -3p on the inhibition of bladder cancer progression.

Uchino K, Takeshita F, Takahashi RU, Kosaka N, Fujiwara K, Naruoka H, Sonoke S, Yano J, Sasaki H, Nozawa S, Yoshiike M, Kitajima K, Chikaraishi T, Ochiya T.

Mol Ther. 2013 Mar;21(3):610-9. doi: 10.1038/mt.2012.269. Epub 2013 Jan 8.

9.

Photomechanical wave-driven delivery of siRNAs targeting intermediate filament proteins promotes functional recovery after spinal cord injury in rats.

Ando T, Sato S, Toyooka T, Kobayashi H, Nawashiro H, Ashida H, Obara M.

PLoS One. 2012;7(12):e51744. doi: 10.1371/journal.pone.0051744. Epub 2012 Dec 14.

10.

TNF-α gene knockout in triple negative breast cancer cell line induces apoptosis.

Pileczki V, Braicu C, Gherman CD, Berindan-Neagoe I.

Int J Mol Sci. 2012 Dec 24;14(1):411-20. doi: 10.3390/ijms14010411.

11.

Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy.

Miele E, Spinelli GP, Miele E, Di Fabrizio E, Ferretti E, Tomao S, Gulino A.

Int J Nanomedicine. 2012;7:3637-57. doi: 10.2147/IJN.S23696. Epub 2012 Jul 20. Review.

12.

Development of an MRI-visible nonviral vector for siRNA delivery targeting gastric cancer.

Chen Y, Wang W, Lian G, Qian C, Wang L, Zeng L, Liao C, Liang B, Huang B, Huang K, Shuai X.

Int J Nanomedicine. 2012;7:359-68. doi: 10.2147/IJN.S24083. Epub 2012 Jan 31.

13.

Anti-proliferation and anti-invasion effects of diosgenin on gastric cancer BGC-823 cells with HIF-1α shRNAs.

Mao ZJ, Tang QJ, Zhang CA, Qin ZF, Pang B, Wei PK, Liu B, Chou YN.

Int J Mol Sci. 2012;13(5):6521-33. doi: 10.3390/ijms13056521. Epub 2012 May 24.

14.

Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth.

Rahman MA, Amin AR, Wang X, Zuckerman JE, Choi CH, Zhou B, Wang D, Nannapaneni S, Koenig L, Chen Z, Chen ZG, Yen Y, Davis ME, Shin DM.

J Control Release. 2012 May 10;159(3):384-92. doi: 10.1016/j.jconrel.2012.01.045. Epub 2012 Feb 8.

15.

Alkane-modified short polyethyleneimine for siRNA delivery.

Schroeder A, Dahlman JE, Sahay G, Love KT, Jiang S, Eltoukhy AA, Levins CG, Wang Y, Anderson DG.

J Control Release. 2012 Jun 10;160(2):172-6. doi: 10.1016/j.jconrel.2011.11.030. Epub 2011 Dec 2.

16.

Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides.

Cheng CJ, Saltzman WM.

Biomaterials. 2011 Sep;32(26):6194-203. doi: 10.1016/j.biomaterials.2011.04.053. Epub 2011 Jun 12.

17.

siRNA targeting Livin decreases tumor in a xenograft model for colon cancer.

Oh BY, Lee RA, Kim KH.

World J Gastroenterol. 2011 May 28;17(20):2563-71. doi: 10.3748/wjg.v17.i20.2563.

18.

Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes.

Saha A, Robertson ES.

Clin Cancer Res. 2011 May 15;17(10):3056-63. doi: 10.1158/1078-0432.CCR-10-2578. Epub 2011 Mar 3. Review.

19.

Delivery of intracellular-acting biologics in pro-apoptotic therapies.

Li H, Nelson CE, Evans BC, Duvall CL.

Curr Pharm Des. 2011;17(3):293-319. Review.

20.

Modeling RNA interference in mammalian cells.

Cuccato G, Polynikis A, Siciliano V, Graziano M, di Bernardo M, di Bernardo D.

BMC Syst Biol. 2011 Jan 27;5:19. doi: 10.1186/1752-0509-5-19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk